Riskpilot← Back to searchSign inGet full accessSagen Läkarkonsult AB
ABActiveOrg 5592127004Skymningsvägen 2Medical specialists activities · NACE 8622Est. 20190 employees
Revenue 2024
SEK 92K
-23% vs 2023
EBITDA margin
33.0%
-59% vs 2023
Equity ratio
76.8%
Financial strength
Net profit 2024
SEK 52K
-11% vs 2023
| Revenue | SEK 92K | -23% |
| EBITDA | SEK 30K | -59% |
| Net profit | SEK 52K | -11% |
| Total assets | SEK 177K | -25% |
| Equity | SEK 136K | +1% |
| Employees | 0 | — |
Legal name
Sagen Läkarkonsult AB
Org number
5592127004
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
17 juli 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att bedriva läkarpraktik, uthyrning av läkartjänster, utbildnings- och forskningsverksamhet samt bedriva förvaltning av värdepapper och fastigheter samt därmed förenlig verksamhet.
Address
Skymningsvägen 2
Email
sagenerik@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 5 | 162 | 141 | 119 | 92 |
| Staff expenses | — | — | — | −1 | −0 |
| EBITDA | −18 | 137 | 113 | 74 | 30 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | −18 | 137 | 113 | 74 | 30 |
| Net financials | — | 3 | — | 0 | 0 |
| Profit before tax | 32 | 105 | 87 | 74 | 66 |
| Tax | −7 | −22 | −18 | −16 | −14 |
| Net profit | 25 | 83 | 69 | 58 | 52 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 119 | 273 | 282 | 235 | 177 |
| Equity | 103 | 186 | 155 | 134 | 136 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 16 | 52 | 66 | 41 | 16 |
| Total debt | 16 | 52 | 66 | 41 | 16 |
EBITDA margin
33.0%
This company
15.8%
Market median
+109% vs market
20202024
Equity ratio
76.8%
This company
38.2%
Market median
+101% vs market
20202024
Return on equity
38.2%
This company
18.4%
Market median
+108% vs market
20202024
Net profit margin
56.5%
This company
8.1%
Market median
+598% vs market
20202024
Asset turnover
0.52×
This company
1.12×
Market median
-54% vs market
20202024
Debt / equity
0.30×
This company
0.62×
Market median
+52% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sagen Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Olof Andreas Sagen | Board of Directors | 0 companies |
| Lydia Mikaela Sagen | Deputy Board Member | 0 companies |